Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics

被引：61

作者：

Scharner, Juergen ^{[1
]}

Aznarez, Isabel ^{[1
]}

机构：

[1] Stoke Therapeut Inc, 45 Wiggins Ave, Bedford, MA 01730 USA

来源：

MOLECULAR THERAPY | 2021年 / 29卷 / 02期

关键词：

antisense oligonucleotides; CpG oligonucleotides; gapmer; RNase H; splicing; steric blocking;

D O I：

10.1016/j.ymthe.2020.12.022

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Single-stranded oligonucleotides have been explored as a therapeutic modality for more than 20 years. Only during the last 5 years have single-stranded oligonucleotides become a modality of choice in the fields of precision medicine and targeted therapeutics. Recently, there have been a number of development efforts involving this modality that have led to treatments for genetic diseases that were once untreatable. This review highlights key applications of single-stranded oligonucleotides that function in a sequence-dependent manner when applied to modulate precursor (pre-)mRNA splicing, gene expression, and immune pathways. These applications have been used to address diseases that range from neurological to muscular to metabolic, as well as to develop vaccines. The wide range of applications denotes the versatility of single-stranded oligonucleotides as a robust therapeutic platform. The focus of this review is centered on approved single-stranded oligonucleotide therapies and the evolution of oligonucleotide therapeutics into novel applications currently in clinical development.

引用

页码：540 / 554

页数：15

共 103 条

[11] Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production [J].

Charleston, Jay S. ;

Schnell, Frederick J. ;

Dworzak, Johannes ;

Donoghue, Cas ;

Lewis, Sarah ;

Chen, Lei ;

Young, G. David ;

Milici, Anthony J. ;

Voss, Jon ;

DeAlwis, Uditha ;

Wentworth, Bruce ;

Rodino-Klapac, Louise R. ;

Sahenk, Zarife ;

Frank, Diane ;

Mendell, Jerry R. .

NEUROLOGY, 2018, 90 (24) :E2146-E2154

[12] Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy [J].

Chiriboga, Claudia A. ;

Swoboda, Kathryn J. ;

Darras, Basil T. ;

Iannaccone, Susan T. ;

Montes, Jacqueline ;

De Vivo, Darryl C. ;

Norris, Daniel A. ;

Bennett, C. Frank ;

Bishop, Kathie M. .

NEUROLOGY, 2016, 86 (10) :890-897

[13] An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis [J].

Crooke, RM ;

Graham, MJ ;

Lemonidis, KM ;

Whipple, CP ;

Koo, S ;

Perera, RJ .

JOURNAL OF LIPID RESEARCH, 2005, 46 (05) :872-884

[14] Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study [J].

De Vivo, Darryl C. ;

Bertini, Enrico ;

Swoboda, Kathryn J. ;

Hwu, Wuh-Liang ;

Crawford, Thomas O. ;

Finkel, Richard S. ;

Kirschner, Janbernd ;

Kuntz, Nancy L. ;

Parsons, Julie A. ;

Ryan, Monique M. ;

Butterfield, Russell J. ;

Topaloglu, Haluk ;

Ben-Omran, Tawfeg ;

Sansone, Valeria A. ;

Jong, Yuh-Jyh ;

Shu, Francy ;

Staropoli, John F. ;

Kerr, Douglas ;

Sandrock, Alfred W. ;

Stebbins, Christopher ;

Petrillo, Marco ;

Braley, Gabriel ;

Johnson, Kristina ;

Foster, Richard ;

Gheuens, Sarah ;

Bhan, Ishir ;

Reyna, Sandra P. ;

Fradette, Stephanie ;

Farwell, Wildon .

NEUROMUSCULAR DISORDERS, 2019, 29 (11) :842-856

[15] Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy [J].

Echigoya, Yusuke ;

Nakamura, Akinori ;

Nagata, Tetsuya ;

Urasawa, Nobuyuki ;

Lim, Kenji Rowel Q. ;

Trieu, Nhu ;

Panesar, Dharminder ;

Kuraoka, Mutsuki ;

Moulton, Hong M. ;

Saito, Takashi ;

Aoki, Yoshitsugu ;

Iversen, Patrick ;

Sazani, Peter ;

Kole, Ryszard ;

Maruyama, Rika ;

Partridge, Terry ;

Takeda, Shin'ichi ;

Yokota, Toshifumi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (16) :4213-4218

[16] Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy [J].

Feldkötter, M ;

Schwarzer, V ;

Wirth, R ;

Wienker, TF ;

Wirth, B .

AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 70 (02) :358-368

[17] Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study [J].

Finkel, Richard S. ;

Chiriboga, Claudia A. ;

Vajsar, Jiri ;

Day, John W. ;

Montes, Jacqueline ;

De Vivo, Darryl C. ;

Yamashita, Mason ;

Rigo, Frank ;

Hung, Gene ;

Schneider, Eugene ;

Norris, Daniel A. ;

Xia, Shuting ;

Bennett, C. Frank ;

Bishop, Kathie M. .

LANCET, 2016, 388 (10063) :3017-3026

[18] Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment [J].

Gait, Michael J. ;

Arzumanov, Andrey A. ;

McClorey, Graham ;

Godfrey, Caroline ;

Betts, Corinne ;

Hammond, Suzan ;

Wood, Matthew J. A. .

NUCLEIC ACID THERAPEUTICS, 2019, 29 (01) :1-12

[19]

Geary R S, 2001, Curr Opin Investig Drugs, V2, P562

[20] Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides [J].

Geary, Richard S. ;

Norris, Daniel ;

Yu, Rosie ;

Bennett, C. Frank .

ADVANCED DRUG DELIVERY REVIEWS, 2015, 87 :46-51

← 1 2 3 4 5 6 7 8 9 10 →